Indinavir anhydrous
As of the edition of 20 October 2026, Indinavir anhydrous is a small molecule: marketed, first approved in 1996 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1996
- Kind
- Small molecule
- Brand name
- Crixivan
- First approved
- 13 March 1996 (US)
- Approvals on record
- 4 in 1 region
- Holder of the most recent approval
- Merck & Co.
- Registered trials
- 92, 6 stopped early
- Disease areas
- Infections; Immune system; Urinary and reproductive; Cancer; Blood and lymph; Digestive system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 29 | 25 | 0 | 4 |
| Phase 1 | 10 | 10 | 0 | 0 |
| Phase 2 | 34 | 27 | 0 | 2 |
| Phase 3 | 13 | 12 | 0 | 0 |
| Phase 4 | 6 | 6 | 0 | 0 |
| All trials | 92 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Originator and Lead sponsor of trials | 1996 to now |